Ironwood Pharmaceuticals
IRWD · Nasdaq · United States
Share price · IRWD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IRWD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+8.9%
- 4 Nov 2026+7.7%
Nothing announced by IRWD that day or the session before.
- 31 Jul 2026+13.4%
Nothing announced by IRWD that day or the session before.
- 13 May 2026-10.0%
- 7 May 2026-13.7%
- 1 Apr 2026+11.1%
Nothing announced by IRWD that day or the session before.
- 2 Jan 2026+26.7%
- 26 Nov 2025+23.3%
Share of unusual movement by asset
For each asset, the share of IRWD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
apraglutideevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 6% |
| Other company news (earnings, financing, releases naming no asset) | — | 34% |
| Sessions with no dated event | — | 60% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
linaclotide(Linzess) | Approved | Guanylate cyclase-C (GC-C)Peptide | Irritable Bowel Syndrome Irritable Bowel Syndrome with Constipation |
| Phase 3 | GLP-2 receptorPeptide | Short Bowel Syndrome |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $133M | $28M | $86M | —$67M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $113M | $22M | $79M | —$58M operating cash flow | report ↗ |
| 2026-Q1 | $107M | $22M | $220M | —$5.1M operating cash flow | report ↗ |
| 2025-Q4 | $48M | — | $215M | $2.3M$75M operating cash flow | report ↗ |
| 2025-Q3 | $122M | $22M | $140M | —$48M operating cash flow | report ↗ |
| 2025-Q2 | $85M | $23M | $93M | —-$15M operating cash flow | report ↗ |
| 2025-Q1 | $41M | $27M | $108M | $37M$20M operating cash flow | report ↗ |
| 2024-Q4 | $91M | — | $89M | —$15M operating cash flow | report ↗ |
| 2024-Q3 | $92M | $30M | $88M | —$9.9M operating cash flow | report ↗ |
| 2024-Q2 | $94M | $30M | $106M | $0.9M$33M operating cash flow | report ↗ |
| 2024-Q1 | $75M | $26M | $122M | $4.2M$45M operating cash flow | report ↗ |
| 2023-Q4 | $118M | — | $92M | $1.1M$36M operating cash flow | report ↗ |
| 2023-Q3 | $114M | $33M | $111M | —$32M operating cash flow | report ↗ |
| 2023-Q2 | $107M | $35M | $177M | $1.1B$35M operating cash flow | report ↗ |
| 2023-Q1 | $104M | $13M | $742M | —$80M operating cash flow | report ↗ |
| 2022-Q4 | $107M | — | $658M | —$79M operating cash flow | report ↗ |
| 2022-Q3 | $109M | $12M | $576M | —$69M operating cash flow | report ↗ |
| 2022-Q2 | $97M | $11M | $506M | —$61M operating cash flow | report ↗ |
| 2022-Q1 | $98M | $11M | $595M | —$64M operating cash flow | report ↗ |
| 2021-Q4 | $117M | — | $622M | —$65M operating cash flow | report ↗ |
| 2021-Q3 | $104M | $11M | $576M | —$75M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $296M | $95M | $215M | —$127M operating cash flow | report ↗ |
Ironwood reported full-year 2025 revenue of $296.15M, down 15.7% YoY, with R&D spend of $95.14M, down 14.6% YoY. The company ended the period with $215.46M in cash and cash equivalents and recorded GAAP net income of $24.02M, or $0.15 per share basic and diluted.
The company reiterated 2026 guidance for LINZESS U.S. net sales of $1.125B to $1.175B, total revenues of $450M to $475M, and adjusted EBITDA above $300M. Key elements of the confirmatory Phase 3 STARS-2 trial design for apraglutide in short bowel syndrome with intestinal failure were finalized, with site initiations expected in Q2 2026. In November 2025, the FDA approved LINZESS for irritable bowel syndrome with constipation in patients aged 7 years and older, and Ironwood settled litigation with Ferring in December 2025, agreeing to pay $12.5M, of which $7.5M was paid and $5.0M is due by December 31, 2026.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($22.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Gaskins Tammi L · Chief Commercial Officer | Open-market sale | 5,919 | $4.81 | $28K | Form 4 |
| 2026-09-15 | DENNER ALEXANDER J · director | Award / grant | 3,694 | — | — | Form 4 |
| 2026-07-20 | Silber Jeffrey · SVP, CMO, Head-Res&Drug | Award / grant | 137,036 | — | — | Form 4 |
| 2026-07-07 | Silver Ronald · PFO & PAO | Open-market sale | 127,890 | $4.52 | $578K | Form 4 |
| 2026-06-16 | Moukheibir Catherine · director | Award / grant | 63,481 | — | — | Form 4 |
| 2026-06-16 | McHugh Julie · director | Award / grant | 63,481 | — | — | Form 4 |
| 2026-06-16 | Duane Jon R · director | Award / grant | 63,481 | — | — | Form 4 |
| 2026-06-16 | Currie Mark G · director | Award / grant | 63,481 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 223 reporting institutions held 160.2M shares ($534.6M, 96.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 15,028,000 | $52.7M |
| 2 | BlackRock, Inc. | 13,362,930 | $46.9M |
| 3 | Sarissa Capital Management LP | 9,188,635 | $32.3M |
| 4 | BANK OF AMERICA CORP /DE/ | 8,682,907 | $30.5M |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 8,061,073 | $28.3M |
| 6 | AQR CAPITAL MANAGEMENT LLC | 7,535,080 | $26.4M |
| 7 | STATE STREET CORP | 7,456,944 | $26.2M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,682,037 | $23.5M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 6,097,454 | $21.4M |
| 10 | TWO SIGMA INVESTMENTS, LP | 5,848,276 | $20.5M |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4,737,857 | $16.6M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 4,543,522 | $16.0M |
| 13 | MARSHALL WACE, LLP | 4,525,064 | $15.9M |
| 14 | JACOBS LEVY EQUITY MANAGEMENT, INC | 3,632,477 | $12.7M |
| 15 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,397,242 | $11.9M |